[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367224-105":59,"doc-detail-367224-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anti-tumor-efficacy-and-safety-of-aev01-in-preclinical-glioblastoma-and-hepatocellular-carcinoma-models","Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models","","Study assesses anti-tumor efficacy and safety of AEV01, a specialized lipophilic extract from Picrorhiza kurroa roots, in preclinical glioblastoma (GB) and hepatocellular carcinoma (HCC) models. In vitro, cytotoxicity and apoptosis are evaluated with MTT assay and AO/EtBr staining, while inflammatory markers and targets are measured using ELISA and immunofluorescence. In vivo, ELISA profiles inflammatory and tumor-suppressor markers and histopathology evaluates tumor morphology and organ toxicity. Results show dose-dependent cytotoxicity, reduced inflammatory and tumor markers, minimal organ toxicity, and favorable safety with TP53 upregulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anti-tumor-efficacy-and-safety-of-aev01-in-preclinical-glioblastoma-and-hepatocellular-carcinoma-models/367224/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anti-tumor-efficacy-and-safety-of-aev01-in-preclinical-glioblastoma-and-hepatocellular-carcinoma-models/367224.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is AEV01 and what is its source?","Question",{"text":112,"@type":113},"AEV01 is a specialized lipophilic extract derived from the roots and rhizomes of Picrorhiza kurroa (Kutki), a Himalayan alpine herb used in traditional Indian medicine.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was AEV01 tested for anti-tumor effects in the study?",{"text":117,"@type":113},"The study evaluated cytotoxicity and apoptosis in vitro using MTT assay and AO/EtBr staining, and used ELISA and immunofluorescence to measure inflammatory markers and targets. In vivo, it used ELISA for inflammatory and tumor-suppressor markers and histopathological analysis for tumor morphology and organ toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding efficacy and safety?",{"text":121,"@type":113},"AEV01 showed dose-dependent cytotoxicity against U-87 MG glioblastoma cells and HepG2 HCC cells, reduced inflammatory and tumor marker expression, upregulated TP53, and demonstrated no significant organ toxicity in xenograft models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367224,1790242579,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAnti‑tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models  \nIndrani Biswas1,5, Senthilathiban Daisy Precilla1,5, Aravinda Kumar2, M. M. Sekhar 3, Renu Medasani3 & T. S. Anitha4*  \nGlioblastoma (GB) and hepatocellular carcinoma (HCC) are aggressive cancers with poor prognoses, often leading to less than a year of survival. Therapeutic resistance underscores the need for novel therapeutic strategies. AEV01, a specialized lipophilic extract derived from the roots of Picrorhiza kurroa, has shown promise as a potential anti‑cancer agent. In this context, the current study aimed to evaluate the anti‑tumor efficacy and safety profile of AEV01 both in vitro and in vivo in GB and HCC models. Briefly, cytotoxicity and apoptosis were assessed using MTT assay and AO/EtBr staining, while ELISA and immunofluorescence measured inflammatory markers like IL‑6, IL‑18, IL‑1β, TNF‑α, CASP‑1, CRP, TP53 and CD36 expression. In vivo, ELISA was performed against the inflammatory and tumor suppressor markers while, histopathological analysis assessed tumor morphology and organ toxicity. AEV01 exhibited dose‑dependent cytotoxicity against U‑87 MG glioblastoma and HepG2 liver cancer cells, with optimal concentrations at 400 µg/ml and 300 µg/ml respectively. Treatment downregulated inflammatory markers, CD36 expression and concomitantly increased TP53 expression. Xenograft models depicted similar results, with reduced tumor markers expression, reduced changes in tissue architecture, and no significant organ toxicity. Thus, AEV01 demonstrated potent anti‑tumor activity with a favorable safety profile, suggesting its potential as a novel therapeutic agent for Glioblastoma and HCC, warranting further clinical investigation.  \nKeywords AEV01, Glioblastoma, Hepatocellular carcinoma, Inflammation, In vitro, In vivo  \nGlioblastoma (GB) and hepatocellular carcinoma (HCC) represent alarming challenges in the field of oncology, characterized by their aggressive nature, poor prognosis, and limited response to existing therapies1,2. Glioblastoma, particularly glioblastoma multiforme (GBM), have a dismal median survival time of approximately 12–15 months despite the use of surgery, radiation, and chemotherapy3. Similarly, HCC, the most common form of primary liver cancer, is associated with high recurrence rates and a median survival of less than a year in advanced stages, even with the application of current standard-of-care treatments such as Sorafenib and Lenvatinib4. Therapeutic efficacies of such existing strategies in combination with the rising challenges of resistance from the context of successful clinical trials, underscores the critical need for novel therapeutic strategies.  \nOrthotopic cell-derived tumor xenograft (CDX) models have provided valuable insights into the complex biology of GB and HCC, aiding in the identification of new therapeutic targets5. These models, which more accurately mimic the human tumor microenvironment compared to subcutaneous models, have been instrumental in preclinical research aimed at identifying and validating new treatment approaches6.  \nIn response to the urgent need for innovative cancer therapies, AEV01, a novel patented drug developed by Astrel Genome Ltd., Hyderabad, India, emerges as a promising candidate. AEV01 is a specialized lipophilic extract derived from the roots and rhizomes of Picrorhiza kurroa, an alpine herb native to the Himalayan region.  \n1Mahatma Gandhi Medical Advanced Research Institute, Sri Balaji Vidyapeeth (Deemed to-be University), Puducherry, India. 2Department of Pharmacology, Pondicherry Institute of Medical Sciences, Ganapathichettikulam, Puducherry, India. 3Astrel Genome Ltd, Hyderabad, India. 4Department of Biochemistry and Molecular Biology, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India. 5Indrani Biswas and Senthilathiban Daisy ","cbCaisAT6JSCxvDD","https://ap.wps.com/l/cbCaisAT6JSCxvDD","pdf",11886728,16,"English","# Background and Rationale\n## Clinical challenge and need for new therapies\n## Preclinical tumor xenograft models\n# Study Drug and Rationale\n## AEV01 origin and bioactive basis\n# Methods Overview\n## In vitro assays for cytotoxicity and apoptosis\n## Inflammatory marker and target measurements\n## In vivo evaluation and histopathology\n# Results Summary\n## Dose-dependent cytotoxicity and target modulation\n## Xenograft tumor marker changes and safety\n# Prior Evidence and Applications\n## Case report observations\n## COVID-19 trial evidence for immune modulation","[{\"question\":\"What is AEV01 and what is its source?\",\"answer\":\"AEV01 is a specialized lipophilic extract derived from the roots and rhizomes of Picrorhiza kurroa (Kutki), a Himalayan alpine herb used in traditional Indian medicine.\"},{\"question\":\"How was AEV01 tested for anti-tumor effects in the study?\",\"answer\":\"The study evaluated cytotoxicity and apoptosis in vitro using MTT assay and AO/EtBr staining, and used ELISA and immunofluorescence to measure inflammatory markers and targets. In vivo, it used ELISA for inflammatory and tumor-suppressor markers and histopathological analysis for tumor morphology and organ toxicity.\"},{\"question\":\"What were the main findings regarding efficacy and safety?\",\"answer\":\"AEV01 showed dose-dependent cytotoxicity against U-87 MG glioblastoma cells and HepG2 HCC cells, reduced inflammatory and tumor marker expression, upregulated TP53, and demonstrated no significant organ toxicity in xenograft models.\"}]","Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models | PDF",1790169767]